Mohlo by sa vám tiež páčiť

Viac informácií o knihe mTOR Inhibition for Cancer Therapy: Past, Present and Future

• Parametre knihy
• Anotácia kniha
• Obľúbené z iného súdka

Nákupom získate 276 bodov

Anotácia knihy

Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation. This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. §

Parametre knihy

Zaradenie knihy Knihy po anglicky Medicine Clinical & internal medicine Diseases & disorders

• Celý názov: mTOR Inhibition for Cancer Therapy: Past, Present and Future
• Autor: Monica Mita, Alain Mita, Eric K. Rowinsky
• Jazyk: Angličtina
• Väzba: Pevná
• Počet strán: 300
• EAN: 9782817804910
• ISBN: 2817804910
• ID: 01984201
• Nakladateľ: Springer Editions
• Hmotnosť: 578 g
• Rozmery: 165 × 245 × 18 mm
• Dátum vydania: 19. November 2015

Obľúbené z iného súdka

---

---

---